Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Roxanne T. Aleman
Advocate Christ Medical Center, United States
Scientific Tracks Abstracts: J Clin Cell Immunol
The unpredictability of the coronavirus disease 2019 (COVID-19) pandemic has created an ongoing global healthcare crisis. Implementation of a mass vaccination program to accelerate disease control remains in progress. Although injection site soreness, fatigue, and fever are the most common adverse reactions reported after a COVID-19 vaccination, ipsilateral lymph node enlargement has increasingly been observed. In patients undergoing routine screening and surveillance for breast cancer, interpreting lymphadenopathy (LAP) is challenging in the setting of a recent COVID-19 vaccination. With a growing proportion of the population receiving the vaccine, a multifaceted approach is necessary to avoid unnecessary and costly workup. Having reviewed 26 published articles, we are able to appreciate how the presence of LAP after the COVID-19 vaccination can impact clinical decision-making. In this comprehensive review, we summarize the existing literature on COVID-19 vaccine-associated LAP in breast imaging patients.
Dr. Roxanne T. Aleman is a third-year internal medicine resident at Advocate Christ Medical Center in Oak Lawn, IL. She received her medical degree from Central Michigan University College of Medicine. Dr. Aleman is an aspiring hematologist and medical oncologist with a keen interest in clinical trials aimed at developing new therapeutic options for patients and addressing cancer health disparities.